Core Insights - LeMaitre Vascular, Inc. reported strong Q2 2025 results, with significant sales growth driven by catheters and grafts, and announced a quarterly dividend of $0.20 per share [1][3][6] Financial Performance - Q2 2025 sales reached $64.2 million, a 15% increase compared to Q2 2024, with organic growth also at 15% [3][10] - Gross margin improved to 70.0%, up from 68.9% in Q2 2024, attributed to higher average selling prices and manufacturing efficiencies [3][10] - Operating income for Q2 was $16.1 million, reflecting a 12% increase year-over-year [3][10] - Earnings per share (EPS) rose 16% to $0.60 per fully diluted share [3][10] Sales Growth Drivers - Sales growth was primarily driven by a 27% increase in catheter sales and a 19% increase in graft sales [3] - Regional sales performance included a 23% increase in EMEA, and 12% growth in both Americas and APAC [3] Guidance and Outlook - The company raised its guidance for Q3 2025, projecting sales between $61.2 million and $63.2 million, and for the full year 2025, sales are expected to be between $248 million and $254 million [4] - Gross margin and operating margin are expected to remain stable at 69.7% and 24% respectively for both Q3 and full year guidance [4] Dividend and Share Repurchase - The Board of Directors approved a quarterly dividend of $0.20 per share, payable on September 4, 2025 [6] - A share repurchase program was authorized for up to $75 million, set to conclude on February 17, 2026, unless extended [7] Cash Position - The company reported a sequential increase in cash of $16.9 million, bringing total cash to $319.5 million [10]

Core Viewpoint - LeMaitre Vascular, Inc. reported strong Q1 2025 results with significant sales growth driven by grafts and carotid shunts, and provided an optimistic sales guidance for the year ahead [1][5]. Financial Performance - Q1 2025 net sales reached $59.9 million, reflecting a 12% increase compared to Q1 2024, with organic growth at 13% [10][21]. - Gross margin improved to 69.2%, up from 68.6% in Q1 2024, attributed to higher average selling prices and manufacturing efficiencies [3][10]. - Operating income was $12.6 million, a 6% increase year-over-year, while operating expenses grew by 16% primarily due to personnel costs [3][10]. - Net income for Q1 2025 was $11.0 million, compared to $9.9 million in Q1 2024, with diluted earnings per share at $0.48, up 10% [21][22]. Sales Growth Drivers - Sales growth was driven by a 17% increase in grafts and a 14% increase in carotid shunts, with regional sales growth of 18% in EMEA, 11% in the Americas, and 3% in APAC [3][10]. - Artegraft, the largest U.S. product, generated $37 million in sales in 2024 and received its MDR CE Mark on April 29, 2025, with a European launch imminent [4]. Guidance and Strategic Initiatives - The company raised its 2025 sales guidance to $245 million, with an organic growth forecast of 13%, up from previous guidance of $239 million and 10% organic growth [5]. - Q2 2025 guidance includes projected sales of $61.5 million to $63.5 million, with a gross margin of 69.5% and operating income between $14.6 million and $16.0 million [5]. Dividend and Share Repurchase - A quarterly dividend of $0.20 per share was approved, to be paid on May 29, 2025 [7]. - The company has authorized a share repurchase program of up to $75 million, which may be suspended or discontinued at any time [8].